Mark A Glickman
CIK 1441461 · Co-Chief Executive Officer · last filed 2026-06-08
Mark A Glickman is a Co-Chief Executive Officer who has filed 28 SEC Form 4 insider transactions across 7 companies since 2008. The most recent filing, for NRBO, was dated Jun 8, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $85.5K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$85.5K
7
28
-$1.51M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MetaVia Inc. (NRBO) Delisted | Director | 20,629 | $2.36 | $48.7K | $0 | 4 | 2026-06-08 |
| TXMD | Co-Chief Executive Officer | 1,734 | $2.20 | $3.8K | -$2.2K | 4 | 2022-12-09 |
| ESPR | Chief Commercial Officer | 25,925 | $3.15 | $81.7K | $0 | 1 | 2020-01-03 |
| Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Chief Commercial Officer | 250,188 | — | — | $82.3K | 7 | 2018-03-21 |
| POZEN INC /NC (POZN) Delisted | Chief Commercial Officer | 29,137 | — | — | $0 | 1 | 2015-06-24 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | EVP - Sales and Marketing | 0 | — | — | -$1.59M | 10 | 2015-01-30 |
| OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted | SVP, Sales & Marketing | 36,157 | — | — | $0 | 1 | 2008-07-30 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-08 | MetaVia Inc. (NRBO) Delisted | Grant (A) | +17,186 | $0 | EDGAR |
| 2025-07-01 | MetaVia Inc. (NRBO) Delisted | Grant (A) | +28,147 | $0 | EDGAR |
| 2024-06-07 | MetaVia Inc. (NRBO) Delisted | Grant (A) | +5,051 | $0 | EDGAR |
| 2023-07-28 | MetaVia Inc. (NRBO) Delisted | Grant (A) | +37,500 | $0 | EDGAR |
| 2022-12-09 | TXMD | Mixed | +1,294 | -$2.2K | EDGAR |
| 2022-03-31 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2022-03-28 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2021-10-15 | TXMD | Grant (A) | — | $0 | EDGAR |
| 2020-01-03 | ESPR | Grant (A) | +5,925 | $0 | EDGAR |
| 2018-03-21 | Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Sell (S) | −5,725 | -$9.7K | EDGAR |